The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Merck Sharp & Dohme; Myriad Pharmaceuticals; NeraCare GmbH; Novartis
Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.
 
Irene L.M. Reijers
No Relationships to Disclose
 
Petros Dimitriadis
No Relationships to Disclose
 
Elisa A. Rozeman
No Relationships to Disclose
 
Judith M. Versluis
No Relationships to Disclose
 
Annegien Broeks
No Relationships to Disclose
 
Linda J.W. Bosch
No Relationships to Disclose
 
Jasper Bouwman
No Relationships to Disclose
 
Sten Cornelissen
No Relationships to Disclose
 
Oscar Krijgsman
No Relationships to Disclose
 
Maria Gonzalez
No Relationships to Disclose
 
Disha Rao
No Relationships to Disclose
 
Lindsay G Grijpink-Ongering
No Relationships to Disclose
 
Marloes van Dijk
No Relationships to Disclose
 
Andrew Spillane
Honoraria - Stryker
 
Richard A. Scolyer
No Relationships to Disclose
 
Bart A. Van De Wiel
No Relationships to Disclose
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD Oncology (Inst); Novartis (Inst); Sanofi (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Bristol-Myers Squibb; GlaxoSmithKline UK Ltd.; Hexal; MERCK; Novartis; OncoSec; Pierre Fabre; Roche
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb